The effect of selenium supplementation in moderate-to-severe thyroid eye disease patients : a randomized-placebo controlled trial
Phase 4
Completed
- Conditions
- Moderate-to-severe thyroid eye disease patientsInactive
- Registration Number
- TCTR20170827002
- Lead Sponsor
- The Ratchadapiseksompotch Fund, Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 46
Inclusion Criteria
1.The patients who have been categorized into moderate-to-severe thyroid eye disease group according to EUGOGO recommendation.
2. Age above 18 years old
3. The patients with normal thyroid hormone level (FT4, FT3) for at least 6 months
4. The patients who presented with thyroid eye symptoms of less than 18 months.
Exclusion Criteria
1. The patients who have history of allergic reaction to selenium
2. The patients who previously took or who are currently taking selenium supplement.
3. The patients who are pregnant or breast-feeding.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical activity score in moderate-to-severe thyroid eye disease patients 6 months Clinical activity score changes
- Secondary Outcome Measures
Name Time Method GO-QOL questionnaire score, overall eye examination, serum selenium levels 6 months GO-QOL questionnaire score, overall eye examination, and serum selenium levels changes